Introduction
Bcl-2 proteins play a critical role in the regulation of apoptosis. The antiapoptotic members of the family include Bcl-2, Bcl-xL, Mcl-1, and others, and the proapoptotic members can be divided into two subgroups: the Bax subfamily (Bax, Bak, and Bok), which contain multiple BH domains, and the BH3-only family (Bad, Bid, Bim, Noxa, Hrk, and others) (Huang and Strasser, 2000; Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003; Scorrano and Korsmeyer, 2003; Tsujimoto, 2003) . The BH3-only proteins are essential initiators of apoptosis (Huang and Strasser, 2000) . They are kept in a latent state and become activated through post-translational modification or transcriptional activation in response to specific apoptotic stimuli. For example, in healthy cells, Bad is sequestered via phosphorylation, Bim is restrained on microtubules, and Bid is inert until cleaved, and several BH3-only genes, including those for Noxa, Hrk, and Bim, are subject to transcriptional regulation. Activated BH-3 proteins then translocate to the mitochondria where they are thought to play a dual role in inactivation of antiapoptotic Bcl-2 proteins and activation of Bax subfamily proteins. This leads to an increase in outer mitochondrial membrane permeability and release of cytochrome c and other apoptogenic factors (Huang and Strasser, 2000; Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003; Scorrano and Korsmeyer, 2003; Tsujimoto, 2003) .
The antiapoptotic Bcl-2 protein undergoes several types of phosphorylation (Ruvolo et al., 2001) . One of these occurs during mitosis in unstressed cycling cells, and involves only a proportion of the Bcl-2 molecules, apparently phosphorylated at a single site, identified in one study as Thr 56 (Furukawa et al., 2000) . Two kinases, CDK1/cyclin B (Furukawa et al., 2000) and JNK (Yamamoto et al., 1999) , have been implicated in this type of Bcl-2 phosphorylation; recent work from our laboratory supports the finding that mitotic Bcl-2 phosphorylation is CDK-dependent (Du et al., 2004) . However, the role of this modification during mitosis remains unknown. A second, prominent form of phosphorylation occurs in response to treatment of cells with antimitotic drugs, such as paclitaxel and vinca alkaloids (Ruvolo et al., 2001 ). This type of phosphorylation appears to involve all Bcl-2 molecules phosphorylated to relatively high levels of two to three or more phosphates/molecule, with phosphorylation reported to occur in the unstructured loop region (Chang et al., 1997; Fang et al., 1998) . Several different kinases or kinase pathways have been implicated in antimitotic drug-induced Bcl-2 phosphorylation, including Raf-1 (Blagosklonny et al., 1997) , JNK (Yamamoto et al., 1999; Fan et al., 2000b) , PKA (Srivastava et al., 1998) , CDK1 (Pathan et al., 2001) , and mTOR (Calastretti et al., 2001) .
The role of the extensive phosphorylation of Bcl-2 occurring in response to microtubule inhibitors is controversial. Deletion of the loop region increases resistance to paclitaxel in several cell lines (Srivastava et al., 1999; Wang et al., 1999) , but sensitizes other cell lines (Fang et al., 1998) . Results from studies where phosphorylation sites have been mutated have also generated contradictory data. For example, some cell lines expressing phospho-defective forms of Bcl-2 are more resistant to microtubule inhibitors, suggesting that phosphorylation disables Bcl-2 antiapoptotic function (Srivastava et al., 1999; Yamamoto et al., 1999) . However, other reports suggest that drug-induced multisite phosphorylation may stabilize Bcl-2 and promote its antiapoptosis function (Brichese et al., 2002) .
In contrast to Bcl-2, which undergoes certain types of phosphorylation in growing healthy cells, Bcl-xL phosphorylation has only been demonstrated in response to apoptotic stress signals, in particular, microtubule inhibitors (Poruchynsky et al., 1998) , and in one report, ionizing radiation (Kharbanda et al., 2000) . Bcl-xL was found to be phosphorylated in many different cell lines in response to several different antimitotic drugs (Poruchynsky et al., 1998) , suggesting that, like multisite Bcl-2 phosphorylation, Bcl-xL phosphorylation is a universal response to microtubule damage. Information on the kinase(s) involved is scarce. In a recent study, paclitaxel-induced Bcl-xL phosphorylation was reported to occur on Ser 62 and to be catalysed by JNK (Basu and Haldar, 2003) . However, phosphorylation of Bcl-xL by JNK in vitro was reported in another study to occur not on serine but on threonine residues (Kharbanda et al., 2000) . Overall, very little is known concerning the enzymology or functional significance of antimitotic drug-induced Bcl-xL phosphorylation, despite the key role played by Bcl-xL in drug sensitivity (Amundson et al., 2000) .
In this paper, we have examined the characteristics of vinblastine-induced Bcl-xL and Bcl-2 phosphorylation in KB-3 cells. We show that these key antiapoptotic proteins undergo a well-defined and highly coordinated cycle of phosphorylation and dephosphorylation, with apoptosis induction being closely associated with their dephosphorylation. Specific and validated inhibitors of JNK, ERK, p38 MAPK , and CDK1 fail to inhibit vinblastine-induced Bcl-xL/Bcl-2 phosphorylation, and recombinant and native Bcl-xL and Bcl-2 are shown to be ineffective in vitro JNK substrates. In addition, BclxL kinase activity is demonstrated in the mitochondrial fraction of vinblastine-treated, but not untreated, KB-3 cells. These results exclude JNK and several other candidate kinases as being responsible for vinblastineinduced Bcl-xL/Bcl-2 phosphorylation, and suggest that a novel or unsuspected kinase, activated in response to microtubule damage, is involved.
Results
Time course of Bcl-xL/Bcl-2 phosphorylation and relation to JNK activation and apoptosis induction KB-3 cells were treated with 30 nM vinblastine for periods up to 48 h, cell extracts were prepared, and subjected to immunoblotting with antibodies to Bcl-xL, Bcl-2, phospho-c-Jun, PARP, and cyclin B ( Figure 1a) . As shown previously (Fan et al., 2000a) , Bcl-xL appeared as a closely spaced doublet, with the upper band undergoing a mobility shift beginning at 12-16 h of treatment ( Figure 1a ). The mobility shift was sensitive to phosphatase treatment, but not if phosphatase inhibitors were present in the incubation, indicating that the shift is due to phosphorylation (Figure 1b) . The phosphorylated form was maintained for a lengthy period up to 32 h, with dephosphorylation evident at 36-48 h. The phosphorylated form of Bcl-xL appeared more abundant than the unphosphorylated form (Figure 1a and b) . Further experiments will be required to determine whether this reflects increased protein abundance, increased immunoreactivity, or both. Bcl-2 phosphorylation followed an essentially identical time course (Figure 1a ). In this case, multiple mobility shifted forms that were phosphatase-sensitive were apparent (Figure 1b) , suggesting multisite phosphorylation. It should be noted that incubation of the samples under nondenaturing conditions at 301C (Figure 1b) led to a certain degree of endogenous dephosphorylation of Bcl-2 in the absence of acid phosphatase, which accounts for the apparent less extensive phosphorylation in Figure 1b than the corresponding sample in Figure 1a .
In order to further demonstrate that Bcl-2 undergoes a cycle of phosphorylation and dephosphorylation, returning to a nonphosphorylated form after 48 h treatment, samples from 0 and 48 h treatment times were analyzed side-by-side and after mixing (Figure 1c , three left lanes). It is evident that the gel mobilities of Bcl-2 in these samples are identical, indicating full reversal of phosphorylative modification. For both Bcl-xL and Bcl-2, protein levels after 48 h exposure to vinblastine were similar to those in control cells, suggesting that the phosphorylation and dephosphorylation cycle does not promote net protein synthesis or degradation. Phosphorylation of c-Jun, evaluated with a phospho-specific (Ser 63) antibody, followed a similar time course, with the phosphorylated form evident at 12-32 h, corresponding to the time of maximum Bcl-xL/Bcl-2 phosphorylation ( Figure 1a) . The possibility that JNK may be responsible for Bcl-xL/Bcl-2 phosphorylation is addressed in experiments described below. Interestingly, PARP cleavage was most noticeably evident between 32 and 36 h of treatment, corresponding to the time of Bcl-xL/Bcl-2 dephosphorylation (Figure 1a) . The relation between these parameters is further addressed in experiments using synchronized cells, as described below. Cyclin B levels also increased as expected with vinblastine treatment, with eventual loss of expression as apoptosis proceeded at late time points (Figure 1a) .
To confirm that vinblastine induced Bcl-xL phosphorylation, KB-3 cells were treated with or without 30 nM vinblastine for 16 h, with phosphate-free medium containing 0.2 mCi/ml 32 P-orthophosphate for the final 2 h. Lysates of labeled cells were immunoprecipitated with Bcl-xL antibody and duplicate samples analysed either by SDS-PAGE, Coomassie staining, and autoradiography, or by immunoblotting for Bcl-xL. As shown in Figure 1d , a 32 P-labeled band was observed in the immunoprecipitate from vinblastine-treated cells but not from control cells. The band migrated with an apparent molecular weight of approximately 32 kDa, exactly in the position of the shifted Bcl-xL immunoreactive band observed in duplicate samples analysed by immunoblotting. To confirm that the mobility shifted immunoreactive band corresponded to the 32 P-labeled band, the ECL signal of the immunoblot was allowed to decay completely, and the membrane itself subjected to autoradiography ( Figure 1d , lower panel). These results confirm that vinblastine induces phosphorylation of BclxL, whereas 32 P-phosphorylated Bcl-xL was not detected in untreated cells.
Vinblastine-induced Bcl-xL/Bcl-2 phosphorylation differs from that during normal mitosis Microtubule inhibitors characteristically induce metaphase arrest prior to apoptosis, and an important question is whether Bcl-xL/Bcl-2 phosphorylation reflects mitosis-or apoptosis-specific events. We have reported previously that Bcl-xL does not undergo phosphorylation during normal mitosis (Fan et al., 2000a) , whereas an independent study reported Bcl-xL phosphorylation at G2/M phase (Basu and Haldar, 2003) . In another study, Bcl-2 phosphorylation was found associated with mitotic arrest and not with the extent of apoptosis in paclitaxel-treated cells (Ling et al., 1998) . In order to clarify these interrelationships, we examined KB-3 cells synchronized by the double thymidine block method, as described in Materials and methods. Cells were harvested before release from the block in G1/S phase, and at 8 h postrelease, in late G2/M phase. Cells in G1/S phase expressed unphosphorylated Bcl-xL, as did cells in late G2/M phase, indicating that Bcl-xL does not undergo mitosisassociated phosphorylation (Figure 2) . In contrast, a proportion of the Bcl-2 population was phosphorylated at G2/M phase, compared to the more extensive phosphorylation observed after vinblastine treatment, highlighting these different forms of Bcl-2 phosphorylation (Figure 2 ). Pphosphate. KB-3 cells were treated with or without 30 nM vinblastine (VBL) for 13.5 h in complete culture medium followed by 30 min incubation in phosphate-free medium containing vinblastine. Cells were then labeled with the same medium containing 0.2 mCi/ml 32 P-orthophosphate for 2 h. Lysates were immunoprecipitated with Bcl-xL antibody and subjected to SDS-PAGE. Duplicate samples were analysed either by Coomassie staining and autoradiography (top panel), or by immunoblotting for Bcl-xL (middle panel) with subsequent 32 P-autoradiography of the immunoblot (lower panel)
Lethal, approximately equitoxic concentrations of the drugs were used, sufficient to initiate apoptotic cell death (monitored by PARP cleavage) after about 28 h, and to reduce absorbance to background levels in MTT cell viability assays after 72 h (data not shown). As shown in Figure 3 , all four microtubule inhibitors promoted phosphorylation of Bcl-xL and multisite phosphorylation of Bcl-2. However, no phosphorylation was observed when cells were treated with equitoxic concentrations of doxorubicin or VP-16, suggesting that these modifications are specific responses to microtubule damage.
Vinblastine-induced Bcl-xL/Bcl-2 phosphorylation is unaltered by JNK inhibition
Vinblastine activates JNK and induces c-Jun phosphorylation as well as phosphorylation of Bcl-xL and Bcl-2 with similar kinetics (Fan et al., 2000a ; Figure 1a ).
Inhibition of JNK had also been suggested to inhibit Bcl-2 phosphorylation induced by microtubule inhibitors in earlier studies (Yamamoto et al., 1999; Fan et al., 2000b) . The availability of SP600125, a pharmacological JNK inhibitor (Bennett et al., 2001) , provided an opportunity to readdress this issue, and directly test whether JNK was responsible for vinblastine-induced Bcl-xL and Bcl-2 phosphorylation. Treatment of KB-3 cells with vinblastine resulted in robust induction of cJun and c-Jun phosphorylation, which was nearly completely inhibited by SP600125 (Figure 4 ). However, under identical conditions and in the same samples, vinblastine-induced phosphorylation of Bcl-xL was completely unaffected. Likewise, SP600125 had little effect on multisite Bcl-2 phosphorylation. The presence of an unphosphorylated Bcl-2 species in VBL/SP600125 cotreated samples is related to the fact that SP600125 delays cell cycle progression (Du et al., 2004) and thus the onset of mitotic block induced by vinblastine, and by the use of asynchronous cells (see Figure 7 below). The results of Figure 4 provide compelling evidence that JNK is not involved in vinblastine-induced Bcl-xL or Bcl-2 phosphorylation.
Bcl-xL and Bcl-2 are ineffective JNK substrates in vitro A previous report suggested that Bcl-xL could serve as an in vitro substrate for JNK (Kharbanda et al., 2000) , although no quantitation was presented to indicate how effective Bcl-xL was compared to other JNK substrates. This report, together with the data presented above in Figure 4 , prompted us to investigate the ability of JNK to phosphorylate Bcl-xL and Bcl-2 in vitro. For this purpose we used a purified, activated form of JNK1 incubated with purified His-tagged proteins and [g-32 P]ATP. Two fusion proteins, GST-c-Jun, containing amino-terminal residues 1-79 of c-Jun, and GST-ATF2, containing amino-terminal residues 1-96 of ATF2, were used as positive controls. Purified JNK effectively phosphorylated the fusion protein substrates as expected, but phosphate incorporation into Bcl-xL or Bcl- Figure 2 Bcl-xL/Bcl-2 phosphorylation in response to vinblastine differs from that occurring during mitosis. KB-3 cells were synchronized at G1/S phase by the double thymidine block method and cell extracts prepared at that time, or after 8 h following release, at G2/M phase (Fan et al., 2000a) . Samples from vinblastine-treated cells (30 nM, 24 h) were analysed in the right lanes for comparison (VBL). Immunoblotting was performed for the indicated proteins P-phosphate incorporation into the different proteins after phosphorimager analysis was performed as described in Materials and methods. With 32 P-phosphate incorporation into cJun set at 100%, phosphate incorporation under these conditions was 119% for ATF2, 1.3% for Bcl-xL, and 2.6% for Bcl-2. Similar results were obtained in one repeat of this experiment. Mitochondria were also used as a source of native Bcl-xL and Bcl-2, and incubated with purified JNK and [g- Vinblastine-induced phosphorylation of Bcl-xL and Bcl-2 are unaffected by inhibitors of ERK, p38, or CDK1
The putative phosphorylation sites in Bcl-2 conform to those recognized by proline-directed kinases including MAPKs, CDKs, and other kinases (Ruvolo et al., 2001) . To further investigate the nature of the vinblastineactivated Bcl-xL/Bcl-2 kinase, inhibitors of ERK, p38 MAPK , and CDK1 were utilized. We considered ERK and p38 unlikely candidates because vinblastine induces their near complete inactivation (Stone and Chambers, 2000) , concurrent with Bcl-xL/Bcl-2 phosphorylation, but it is still possible that residual activity of these kinases might be responsible. KB-3 cells express constitutively activated ERK1/2, as shown by immunoblotting with an antibody recognizing activated, phosphorylated ERK1/2 (Stone and Chambers, 2000) , and the MEK inhibitor UO126 effectively inhibited basal ERK phosphorylation (Figure 6a) . Treatment of cells with vinblastine caused inactivation of ERK, as did treatment with both UO126 and vinblastine as expected, while vinblastine-induced Bcl-xL and Bcl-2 phosphorylation occurred normally (Figure 6a) . Similarly, the p38 inhibitor SB202190 failed to inhibit vinblastine-induced Bcl-xL/Bcl-2 phosphorylation, despite the ability to inhibit basal and phorbol ester-stimulated p38 activity (Osborn et al., 1999) . These findings suggest that vinblastine-induced Bcl-xL/Bcl-2 phosphorylation is not catalysed by ERK or p38.
CDK1 is another candidate kinase since it is activated during mitotic progression, exhibits sustained activity in mitotically arrested cells, and appears to play a role in mitotic Bcl-2 phosphorylation (Furukawa et al., 2000; Du et al., 2004) . Roscovitine is a relatively specific inhibitor of several different CDKs including CDK1 (Bain et al., 2003) . We utilized synchronized cells, as in Figure 5 Bcl-xL and Bcl-2 are ineffective JNK substrates in vitro. GST-c-Jun, GST-ATF2, His-Bcl-xL, or His-Bcl-2 were incubated with purified, activated JNK1 and [g-32 P]ATP under phosphorylation conditions, as described under Materials and methods. After 10 min at 301C, reactions were terminated and subjected to SDS-PAGE and analysed for Four plates of KB-3 cells were synchronized at G1-S; two were left untreated and two were treated with 30 nM vinblastine (VBL) 1 h after release from G1-S. After 12 h, one from each group was treated with 25 mM roscovitine for 2 h. Cells were harvested and extracts were subjected to SDS-PAGE and immunoblotting for the indicated proteins. A phospho-specific H1 histone antibody was used Figure 2 , because we could add the kinase inhibitor for a brief period at a specified point in the cycle to monitor its effects on phosphorylation, without the complication of disturbing orderly cell cycle progression. The experimental design was to have four sets of cells synchronized at G1-S by the double thymidine block; two were left untreated and two were treated with vinblastine 1 h after release from G1-S. After 12 h, one from each group was treated with 25 mM roscovitine for 2 h. Cells were harvested and extracts were subjected to SDS-PAGE and immunoblotting with several different antibodies (Figure 6b ). Vinblastine induced cyclin B accumulation, phosphorylation of H1 histone, a marker of CDK1 activity, and phosphorylation of Bcl-xL and Bcl-2, as expected. Roscovitine alone had no effect relative to control cells on these parameters (in the absence of vinblastine-induced mitotic arrest, the cells had proceeded into the next G1 phase before roscovitine addition). In vinblastine-treated cells, subsequently treated with roscovitine, H1 histone phosphorylation was strongly inhibited. Thus, the presence of roscovitine during this 2 h period was clearly sufficient to inhibit the sustained CDK1 activity exhibited by the vinblastinetreated cells. However, cyclin B levels were still elevated, indicating that the presence of roscovitine during this brief period did not prevent mitotic block, as anticipated from the experimental design. In this last group of samples, vinblastine-induced phosphorylation of Bcl-xL and Bcl-2 was clearly unaffected. These results provide compelling evidence that CDK1 is not responsible for vinblastine-induced Bcl-xL/Bcl-2 phosphorylation.
Bcl-xL and Bcl-2 undergo a coordinated cycle of phosphorylation/dephosphorylation which is delayed but not inhibited by JNK inhibition
In an asynchronous population treated with vinblastine, cells near mitosis at the start of treatment would be expected to initiate Bcl-xL/Bcl-2 phosphorylation much earlier than cells in G1, and in the former group, dephosphorylation might begin prior to maximum phosphorylation in the latter group if phosphorylation was a reversible event. Therefore, to obtain a clearer picture of these reversible events, we studied these parameters in synchronized cells. Several flasks of KB-3 cells were released from double-thymidine block, after 2 h treated with vinblastine, harvested at defined time intervals thereafter, and extracts subjected to immunoblotting. As shown in Figure 7a (left panel), cyclin B levels began to increase around 8 h post-vinblastine, and H1 and c-Jun were phosphorylated at 12 h and later time points. Bcl-xL and Bcl-2 were first observed to be phosphorylated at 12 h, with gradual dephosphorylation first observed at 28 h. It is evident that their phosphorylation and dephosphorylation occurred in parallel, and maximal phosphorylation was maintained over a lengthy period of up to 16 h. Even more striking was that PARP cleavage was first observed to occur precisely when Bcl-xL/Bcl-2 dephosphorylation began.
To further investigate the relationship between these parameters and determine whether JNK played a role, the same experiment was performed with the JNK inhibitor SP600125 added 1 h prior to vinblastine (Figure 7a , right panel). Several observations are of note. First, vinblastine-induced c-Jun phosphorylation was strongly inhibited, as expected, in confirmation of results obtained with asynchronous cells (Figure 4) . Second, all the other events were initiated with a delay of 4 h or more. This is in keeping with evidence that JNK plays a key role in G2/M phase progression and that inhibition of JNK delays cell cycle progression (Du et al., 2004) . It is evident that inhibition of JNK by SP600125 only delayed but did not inhibit cyclin B accumulation, H1 phosphorylation, and Bcl-xL/Bcl-2 phosphorylation induced in response to vinblastine. Importantly, Bcl-xL phosphorylation/dephosphorylation still occurred in parallel with Bcl-2 phosphorylation/dephosphorylation, despite displacement to later times. Furthermore, PARP cleavage also occurred much later when SP600125 was present, being first evident at 36 h, and this event again correlated well with Bcl-xL/ Bcl-2 dephosphorylation.
In order to confirm the correlation between Bcl-xL/ Bcl-2 dephosphorylation and apoptosis induction, the extent of apoptosis was evaluated independently by DNA analysis using propidium iodide staining and flow cytometry, as described in Materials and methods. In synchronized cells treated with vinblastine, incremental increases in apoptotic DNA were observed at 24, 28, and 36 h (Figure 7b ), in close agreement with the PARP cleavage data of Figure 7a . In synchronized cells treated with vinblastine and SP600125, basal levels of apoptosis were observed at 24 and 28 h, and a significant increase to 28% apoptotic DNA was observed at 36 h. This again paralleled the kinetics of PARP cleavage (Figure 7a) . These results provide an independent measure and comparison of apoptosis induction under the two conditions. Moreover, apoptosis induction was more gradual with time in cells treated with only vinblastine, and Bcl-xL/Bcl-2 dephosphorylation was also more graded. On the other hand, apoptosis induction was more abrupt in cells treated with both vinblastine and SP600125, as was Bcl-xL/Bcl-2 dephosphorylation. Collectively, the results of Figure 7 highlight the close correlation between dephosphorylation of Bcl-xL/Bcl-2 and apoptosis induction. In addition, phosphorylative modification of Bcl-xL appears to be strongly coordinated with that of Bcl-2, suggesting that a common kinase/phosphatase system may be responsible.
Localization of Bcl-xL and Bcl-2 in the mitochondrial fraction and detection of Bcl-xL kinase activity in vinblastine-treated cells
To determine the subcellular location of Bcl-xL and Bcl-2 in KB-3 cells, cytosolic and mitochondrial-enriched fractions were prepared as described in Materials and methods. Caspase 3 was used as a cytosolic marker, and cytochrome c as a mitochondrial marker (Figure 8a) . In control cells, Bcl-2 was detected in the mitochondrial fraction and was not detected in the cytosolic fraction, whereas Bcl-xL was detected in both fractions but more predominately in the mitochondrial fraction. The possibility that Bcl-2 and Bcl-xL are also present in other subcellular organelles remains to be examined. After vinblastine treatment, the phosphorylated forms of Bcl-xL and Bcl-2 were found present in the mitochondrial fraction, indicating that no significant subcellular redistribution had occurred. These findings suggested that the kinase responsible might be detectable in the mitochondrial fraction of vinblastine-treated cells. To investigate this possibility, mitochondrial fractions from control and vinblastine-treated cells were used as a source of kinase activity and incubated with His-tagged Bcl-xL and [g-32 P]ATP. Samples were subjected to immunoprecipitation with Bcl-xL antibody crosslinked to protein A sepharose followed by SDS-PAGE and detection of 32 P-labeled proteins by phosphorimager analysis. A protein of the correct molecular weight, immunoreactive with antibody against the His tag, was preferentially phosphorylated in the extract from vinblastine-treated cells, and was not observed in controls omitting extract or substrate (Figure 8b ).
Discussion
Microtubule inhibitors characteristically promote phosphorylation of Bcl-xL and Bcl-2, two prominent antiapoptotic members of the Bcl-2 family. As these post-translational modifications appear to represent key events in the induction of apoptosis induced by these drugs, elucidation of the enzymology and functional role of Bcl-xL/Bcl-2 phosphorylation is needed to fully understand the molecular mechanism of action of these important agents. In this paper, several novel observations concerning the characteristics of vinblastineinduced phosphorylation of Bcl-xL and Bcl-2 have been presented. Firstly, vinblastine induced a well-defined cycle of phosphorylation and dephosphorylation, and the reversible phosphorylation of Bcl-xL was found to be highly coordinated with that of Bcl-2 under different conditions. These results show that both proteins are modified in tandem and suggest that the same kinase/ phosphatase system may be responsible. Secondly, internally validated inhibitors of MAPKs and CDKs Vinblastine-induced Bcl-xL/Bcl-2 phosphorylation L Du et al failed to inhibit vinblastine-induced Bcl-xL/Bcl-2 phosphorylation. These results suggest that a novel or unsuspected kinase may be responsible, and, as none of the kinase inhibitors was effective, provide additional support for the notion that a common kinase is involved. Thirdly, it was observed that apoptosis induction, evaluated with two independent markers, correlated closely under different conditions with dephosphorylation of Bcl-xL and Bcl-2 (Figures 1a and 7) , whereas the phosphorylated forms of Bcl-xL and Bcl-2 were clearly associated with a preapoptotic state. Finally, we detected Bcl-xL kinase activity in the mitochondrial-enriched fraction of vinblastine-treated cells, whereas control untreated cells exhibited little of this activity (Figure 8 ). This finding, together with the observation that both the unphosphorylated and phosphorylated forms of Bcl-xL and Bcl-2 are largely localized to the mitochondria, suggests that the relevant kinase/phosphatase system acts at the mitochondria to mediate these events.
In confirmation of previous results (Fan et al., 2000a) , phosphorylation of Bcl-xL and extensive phosphorylation of Bcl-2 occur in response to lethal concentrations of vinblastine and other microtubule inhibitors, and are not associated with normal mitosis or DNA damaging agents (Figures 2 and 3) . However, a much less extensive form of Bcl-2 phosphorylation, involving apparently only a proportion of the Bcl-2 molecules, occurs discretely at mitosis (Fan et al., 2000a;  Figure 2 ). Recent work from our laboratory has indicated that this mitotic Bcl-2 phosphorylation is sensitive to inhibition by roscovitine, a CDK inhibitor, but is unaffected by the JNK inhibitor SP600125 (Du et al., 2004) . However, vinblastine-induced multisite Bcl-2 phosphorylation was unaffected by CDK or JNK inhibition (Figures 4 and 7) . These results suggest that Bcl-2 undergoes distinct types of phosphorylation catalysed by several kinases, with mitotic phosphorylation catalysed by CDK or a CDKregulated kinase, and vinblastine-induced phosphorylation mediated by a different, as yet unidentified, kinase. In contrast to our results, which indicate that Bcl-xL is not phosphorylated in untreated cells at any point in the cell cycle, one report suggested that Bcl-xL was phosphorylated at G2/M phase (Basu and Haldar, 2003) . However, in that study, rather than collecting untreated G2/M phase cells, paclitaxel was used to block the cells at metaphase. Thus, the cells utilized did not actually represent a mitotic population, but rather ones treated with a microtubule inhibitor, which would be expected to activate the Bcl-xL kinase. Based on current data it appears that Bcl-xL phosphorylation is a unique event associated with microtubule inhibitor-induced apoptosis.
Several other investigations have been undertaken to identify the kinase responsible for paclitaxel-or vinblastine-induced Bcl-2 phosphorylation. In 293 cells, paclitaxel-induced Bcl-2 phosphorylation was reported to be inhibited by the expression of dominant-negative (dn) kinases in the JNK cascade (Yamamoto et al., 1999) . Specifically, transfection with a combination of dnJNK, dnMKK7, and dnASK1 inhibited paclitaxelinduced phosphorylation of exogenous Bcl-2. Antisense oligonucleotides to JNK1 and JNK2 have also been reported to inhibit vinblastine-induced phosphorylation of Bcl-2 and Bcl-xL (Fan et al., 2000b) . We have now shown that specific inhibition of JNK by an internally validated inhibitor fails to inhibit vinblastine-induced Bcl-xL/Bcl-2 phosphorylation (Figures 4 and 7) . How can these findings be reconciled? The answer may lie in the fact that inhibition of JNK delays phosphorylation. This is most clearly observed in the experiment using synchronized cells in Figure 7 , where the addition of SP600125 delays vinblastine-induced phosphorylation of Bcl-xL/Bcl-2 by at least 4 h. If a single time point is examined, for example, 12 h in Figure 7 , it is easy to conclude that SP600125 inhibits Bcl-xL/Bcl-2 phosphorylation, but this is not so. In the previous studies (Yamamoto et al., 1999; Fan et al., 2000b) , single time Vinblastine-induced Bcl-xL/Bcl-2 phosphorylation L Du et al points of drug treatment were utilized, and the experimental design precluded distinguishing between delay and inhibition. Why does JNK inhibition delay these events? Recent work from several laboratories has indicated that JNK plays a key role in cell proliferation (Potapova et al., 2000a, b; Du et al., 2004) . More specifically, we have shown that JNK is activated in a cell cycle-dependent manner, and that JNK inhibition delays cell cycle transit time especially through S and G2/M phases (Du et al., 2004) . Inhibition of cell cycle progression through JNK inhibition causes a delay in vinblastine-mediated events, including mitotic arrest as well as apoptosis induction (Figure 7 ). These considerations emphasize the importance of making observations over extended time periods to avoid misinterpretation of the results, and also highlight the utility of synchronized cells populations for the study of reversible cell cyclerelated events.
Microtubule inhibitor-induced Bcl-2 phosphorylation was originally proposed as a key step from microtubule damage to cell death (Blagosklonny et al., 1997) , but the molecular mechanisms involved have been difficult to establish. The role of Bcl-2 phosphorylation has been studied largely using mutagenesis. However, a major problem is that many of the putative phosphorylation sites have been identified by inference rather than direct means. For example, potential sites of phosphorylation by JNK were proposed after forced overexpression of JNK and Bcl-2 (Maundrell et al., 1997) , without evidence that JNK was a relevant kinase in vivo. Indeed, when compared with known JNK substrates in vitro, Bcl-xL and Bcl-2 were found to be relatively poorly phosphorylated ( Figure 5 ). The putative sites of phosphorylation lie in an unstructured loop region, and mutation of these sites or deletion of the loop has led to contradictory results. For example, expression of a phospho-defective form of Bcl-2 (Yamamoto et al., 1999) or deletion of the loop region (Srivastava et al., 1999; Wang et al., 1999) was reported to increase resistance to paclitaxel, suggesting that phosphorylation has a disabling or proapoptotic function. However, deletion of the loop did not block paclitaxel-induced apoptosis in another study (Fang et al., 1998) , and phosphorylation of Ser 70 in particular appears to play a key antiapoptotic function (Ito et al., 1997; Ruvolo et al., 2001) .
The data presented here offer some insight into the role of phosphorylation. Most importantly, we have found that the phosphorylated forms of Bcl-2 and BclxL after vinblastine treatment exist for a lengthy period, some 12 h or more, and are associated with a preapoptotic condition (Figure 7) . Thus, both unphosphorylated and phosphorylated Bcl-xL/Bcl-2 molecules are compatible with survival, and this may explain why phospho-defective or phospho-mimic forms of Bcl-2 are not necessarily distinguishable in survival or viability assays. It is not until dephosphorylation is initiated that apoptosis induction is evident, suggesting that reversal of phosphorylation, not phosphorylation per se, acts as a switch for apoptosis induction. Precisely how a cycle of phosphorylation/dephosphorylation may regulate these proteins or their interactions with other factors, and the nature of the enzymes involved in these key events, remain to be determined.
Materials and methods

Materials
SP600125 was synthesized at the Signal Research Division of Celgene Corp. or obtained from Biomol with identical results. Roscovitine was from Calbiochem and U0126 was purchased from Promega. Antibodies to ERK1/2 (sc-93, clone C-16), Bcl-2 (sc-509, clone 100), caspase 3 (sc-7148, clone H-277), and actin (sc-1616, clone I-19) were from Santa Cruz Biotechnology and antibodies to cyclin B (Cat. # 554178, clone GNS-11), cytochrome c (Cat. # 556433, clone 7H8.2C12), and PARP (Cat. # 556494, clone HC10-5) were obtained from Pharmingen. Antibody to c-Jun (Cat. # 610326, clone 3) was from Transduction Laboratories. Phospho-specific antibodies for c-Jun(Ser63) (Cat. # 9261) and ERK (Cat. # 9101), antibody to Bcl-xL (Cat. # 2762), and the GST fusion protein substrates were obtained from Cell Signaling Technology. Phosphospecific antibody for H1 histone (Cat. # 06-597) and purified activated JNK1 were obtained from Upstate Biotechnology. 32 P-orthophosphate and [g-32 P]ATP were obtained from Amersham International. Fetal bovine serum (FBS) was from Hyclone and other cell culture reagents from Life Technologies, Inc. Lambda protein phosphatase was purchased from New England Biolabs. Human recombinant His-Bcl-xL was obtained from Oncogene Research Products. His-Bcl-xL (28 kDa) was truncated by 21 amino acids from the C-terminus and the addition of a His tag also at the C-terminus. Unless otherwise stated, other reagents were from Sigma Chemical Co.
Cell culture and cell synchronization
The KB-3 human carcinoma cell line was maintained in monolayer culture at 371C and 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM), supplemented with 10% FBS, 2 mM L-glutamine, 50 U/ml penicillin, and 50 mg/ml streptomycin. KB-3 cells were synchronized by the double thymidine block method as described previously (Fan et al., 2000a) . Briefly, cells were incubated in medium containing 2 mM thymidine for 16 h, released into normal medium for 9 h, and then incubated for 16 h in medium containing 2 mM thymidine.
Preparation of cell extracts and immunoblotting
Whole-cell extracts were prepared by suspending cells in 0.25 ml of lysis buffer (25 mM HEPES, pH 7.5, 0.3 M NaCl, 0.2% SDS, 0.5% sodium deoxycholate, 0.2 mM EDTA, 0.5 mM dithiothreitol, 20 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 0.1% Triton X-100, 20 mg/ml aprotinin, 50 mg/ml leupeptin, 10 mM pepstatin, 0.1 mM okadaic acid, and 1 mM PMSF). After 15 min on ice, extracts were sonicated (3 Â 10 s), insoluble material was removed by centrifugation (15 min at 12 000 g), and protein concentration in the supernatant was determined using the BioRad protein assay. Immunoblotting was performed using 50 mg protein/lane.
Phosphatase treatment
Cell extracts were prepared by lysing cells under nondenaturing conditions in 10 mM HEPES pH 7.5, 5 mM MgCl 2 , 1 mM EGTA, 0.2% NP-40, 20 mg/ml aprotinin, 1 mM PMSF, and 50 mg/ml leupeptin. Aliquots of 100 mg were incubated with 400 U of lambda protein phosphatase in 25 ml phosphatase buffer (50 mM Tris-HCl, pH 7.5, 0.1 mM EDTA, 5 mM dithiothreitol, 0.01% Brij 35, and 2 mM MnCl 2 ) at 301C for 30 min. In control experiments, phosphatase was inhibited by the addition of 50 mM NaF, 10 mM Na 3 VO 4 , and 0.1 mM okadaic acid. The reaction was stopped by the addition of SDS-PAGE sample buffer. Products were separated by SDS-PAGE and analysed by immunoblotting.
32 P labeling of cells and immunoprecipitation of Bcl-xL KB-3 cells were treated with or without 30 nM vinblastine for 16 h, with phosphate-free medium containing 0.2 mCi/ml [ 32 P]orthophosphate for the final 2 h. Labeled cells were lysed and lysates (100 mg) incubated with 10 ml Bcl-xL antibody and protein A-agarose overnight at 41C, and immunoprecipitates were washed and subjected to SDS-PAGE. Autoradiography was performed using MS X-ray film (Kodak BioMax).
In vitro kinase assays
GST-c-Jun, GST-ATF2, His-Bcl-xL, or His-Bcl-2 (0.5 mg each) were incubated with 5 mU of purified, activated JNK1 in a reaction mixture (25 ml) containing 25 mM MOPS (pH 7.2), 25 mM b-glycerophosphate, 1 mM DTT, 1 mM Na 3 VO 4 , 5 mM MgCl 2 , and 10 mM [g-32 P]ATP (10 000 c.p.m./pmol). After 10 min at 301C, reactions were terminated and subjected to SDS-PAGE. After Coomassie staining, the gel was dried and 32 P-incorporation was evaluated by exposure to phosphorimager screens. The phosphorimager screens were scanned on a Model 445SI phosphorimager, and the scanned files were analysed with the ImageQuaNT software (Molecular Dynamics, Inc.).
Propidium iodide staining and flow cytometry
After treatment, cells were collected by trypsinization, fixed in 70% ethanol, washed in PBS, resuspended in 40 ml of 192 mM Na 2 HPO 4 , 4 mM citric acid, pH 7.8, at room temperature for 30 min. The cells were then stained with 0.5 ml of PBS containing 1 mg/ml RNase and 10 mg/ml propidium iodide, incubated for 20 min in the dark at room temperature, and analysed by flow cytometry using a FACSCalibur (Becton Dickinson, Mountain View). The data were analysed using the ModFit DNA analysis program (Verity Software House).
Preparation of cytosolic and mitochondrial-enriched fractions
Cytosolic and mitochondrial extracts were prepared using a fractionation kit from Active Motif (Cat. No. 40015) according to the manufacturer's instructions. Briefly, 5 Â 10 7 cells were washed with PBS twice, resuspended in 1 ml ice-cold cytosolic buffer, incubated on ice for 15 min, homogenized with 30 strokes of a pestle homogenizer, and centrifuged at 800 g for 20 min. The supernatant was then centrifuged at 10 000 g for 20 min, with the supernatant retained as the cytosolic fraction and the pellet as the mitochondrial-enriched fraction. The latter was resuspended in complete mitochondrial buffer provided in the kit.
Phosphorylation of His-Bcl-xL by mitochondrial extracts
Mitochondrial extracts were prepared from control or vinblastine-treated (30 nM, 16 h) KB-3 cells and 100 mg aliquots were incubated in a kinase reaction buffer containing 50 mM Tris-HCl, pH 7.5, 10 mM MgCl 2 , 5 mM DTT, 10 mM [g-32 P]ATP (10 000 c.p.m./nmol), 70.5 mg His-Bcl-xL, in the presence of phosphatase and protease inhibitors (as above). After incubation at 371C for 30 min, samples were immunoprecipitated with anti-Bcl-xL antibody and protein A sepharose and subjected to SDS-PAGE. 32 P-phosphorylated His-Bcl-xL was detected on a phosphorimager screen and by immunoblotting using an anti-His tag antibody. Immunoprecipitation was performed with Bcl-xL antibody covalently linked to protein A sepharose which was prepared using the Seize Xt Immunoprecipitation Kit following the manufacturer's instructions (Pierce Biotechnology, Cat. # 45215). Briefly, 20 mg Bcl-xL antibody was mixed with 0.4 ml active protein A beads and crosslinked using disuccinimidyl suberate, and unbound antibody removed with washing buffer provided in the kit.
